CB-839 has been reported to be effective for several types of solid cancers [34,35] and hematological malignancies [36,37] and many clinical trials of CB-839, including targeting PIK3CA-mutated CRC (ClinicalTrials.gov identifier: NCT02861300), are ongoing. This evidence concerns the gene PIK3CA and hematologic disorder.